A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers

Brief description of study

This study is testing a new cancer treatment called MK-2870 to see if it has few side effects and works well for patients with certain types of gastrointestinal (GI) cancers. Patients will join the study and be placed into one of three groups based on their type of cancer: patients with colorectal cancer (CRC), patients with pancreatic cancer (PDAC), and patients with biliary tract cancer (BTC). The study will check for side effects and see how well the treatment helps shrink tumors. For the CRC group, the study will first test the safety and side effects of MK-2870 with another drug, a combination of 5-FU (5-fluorouracil) and LV (leucovorin), before moving on to see how well it works. Any side effects will be carefully tracked and reported.


Clinical Study Identifier: s23-01574
ClinicalTrials.gov Identifier: NCT06428409
Principal Investigator: Paul E. Oberstein.
Other Investigators: Daniel J Becker, Marta Wioleta Wronska, Kristen Spencer, Monica Rivera, Keriann M Scavone, Nina Beri, Michael Shusterman, Rafael Winograd, Shun Yu, Alexander A Hindenburg.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.